Search Results for: SRPT
One of Cathie Wood's Ark Invest funds sold over 1.5 million shares of Workhorse on May 11.
Published:
A couple of Cathie Wood's ARK Invest funds sold over 150,000 shares of Alibaba on August 16.
Published:
China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.
Published:
Sarepta Therapeutics cleared another hurdle related to its Duchenne muscular dystrophy treatment, and the stock practically doubled on Monday.
Published:
Last Updated:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a company which many biohealth and biotech investors have likely never heard of. At least before today. How many shares rise more than 150% when there is...
Published:
Last Updated:
The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola drugs might not be a cure-all for patients.
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, October 28, 2014.
Published:
Barclays recently issued a few calls across multiple industries implying serious upside for each stock, but one in particular with over 30% upside.
Published:
One of Cathie Wood's Ark Invest funds sold over 500,000 shares of Huya on May 14.
Published:
Amicus Therapeutics is another biotech player seeing a nice boost from the World Muscle Society Conference in France.
Published:
Last Updated:
Sarepta Therapeutics shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot.
Published:
Wednesday's leading analyst upgrades, downgrades and initiations from top research calls from around Wall Street include Exxon, Lowe's, Paycom Software, Under Armour, Wal-Mart and Verizon...
Published:
One of Cathie Wood's Ark Invest funds sold over 831,000 shares of Pure Storage on May 13.
Published:
Catabasis Pharmaceuticals shares continued their incredible climb after the announcement of positive efficacy results from its MoveDMD trial in a late-breaking session at the World Muscle Society...
Published:
Last Updated:
Credit Suisse's $36 price target on Sarepta Therapeutics effectively calls for close to 75% upside.
Published: